John Volpone Email

EVP and Chief Staff . CTI BioPharma

Current Roles

Employees:
211
Revenue:
$32.7M
About
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO^TM is a trademark of CTI BioPharma Corp.
CTI BioPharma Address
3101 Western Ave., #600
Seattle, WA
United States
CTI BioPharma Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.